Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
← Research & Industry News
External source

Personalized mRNA cancer vaccine cuts melanoma recurrence risk when added to immunotherapy

Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase 3 INTerpath-001 trial presented at the ESMO Congress 2026.

Published by
News-Medical
Evidence type
Clinical

Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase 3 INTerpath-001 trial presented at the ESMO Congress 2026.

This item was selected automatically by our daily literature and news monitor because it matches the topics we follow. Read the full story at News-Medical.

Gene Delivery & TransfectionClinical & Regulatory

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.
Personalized mRNA cancer vaccine cuts melanoma recurrence risk when added to immunotherapy | Brilliant Blue Biosciences